How effective is the Indian NATCO version of Pomalidomide treatment? Is there anything to pay attention to when patients stop taking medication?
Pomalidomide is a third-generation immunomodulatory agent mainly used for the treatment of relapsed/refractory multiple myeloma, with significant efficacy but strict management of the discontinuation process is required. The following provides a detailed explanation from two aspects: treatment effectiveness and precautions for discontinuing medication.
1. Therapeutic effect
(1) Overall relief rate
In key phase III clinical trials, the overall response rate of pomalidomide combined with low-dose dexamethasone was 30% -40%, with a median progression free survival of approximately 4 months, significantly better than the control group.
(2) Special population response
Patients resistant to lenalidomide can still achieve a response rate of 21.5%, while those resistant to bortezomib have a response rate of 29.2%, indicating low cross resistance.
(3) Survival benefits
The median overall survival can reach 12-15 months, which is 3-5 months longer than the traditional protocol, and the quality of life score is significantly improved.
2. Precautions for discontinuation of medication
(1) Standard discontinuation process
It is necessary to gradually reduce the dosage under the guidance of a doctor, usually by 50% every 2 weeks, to avoid sudden cessation of medication leading to disease rebound or withdrawal reactions.
(2) Adverse reaction monitoring
After discontinuing the medication, continuous monitoring of blood routine (especially neutrophils), liver function, and deep vein thrombosis symptoms should be carried out for at least 2 months.
(3) Management of special populations
Patients with renal insufficiency need to extend the monitoring period after discontinuing medication; Women of childbearing age still need to use contraception for at least 4 weeks after discontinuing medication.
(4) Recurrent treatment
After stopping the medication, the disease progression may consider restarting treatment, but it is necessary to evaluate the previous toxicity and current physical condition, and adjust the combination therapy plan if necessary.
3. Risk Warning
Delayed neutropenia or hepatotoxicity may still occur after discontinuation of medication, and regular follow-up is necessary; Pregnant women should seek medical attention immediately after being exposed to medication.
Disclaimer：《How effective is the Indian NATCO version of Pomalidomide treatment? Is there anything to pay attention to when patients stop taking medication?》Edited and sorted by Seagull Pharmacy's editors. Please contact us in time if there is any infringement. In addition, the suggestions for drug usage, dosage and disease mentioned in the article are only for medical staff's reference, and can not be used as any basis for medication！